GSK shares were down 3.9%, as of 0958 GMT, after earlier hitting their lowest since November 2023. Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.

GSK reveals steep fall in vaccine sales, backs outlook 07:13 , Graeme Evans GSK today reported a ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

GSK is delivering consistent financial performance ... and six with national reimbursement programs. More rollouts across Europe and international will come in 2025. For Shingrix, year-to-date ...

European markets are heading for a negative open Wednesday, as investors await the latest growth data from the region and ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

European stocks closed broadly higher on Tuesday with investors largely making cautious moves, digesting mixed earnings updates and ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...